Trial Profile
A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Subjects With Impaired Renal Function.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Cilastatin/imipenem/relebactam (Primary) ; Caffeine; Imipenem/cilastatin; Midazolam; Omeprazole
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 21 Mar 2012 Actual patient number added 49 according to ClinicalTrials.gov.
- 21 Mar 2012 Actual end date (March 2012) added as reported by ClinicalTrials.gov.
- 21 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.